Tag: Dr Stephen Tilles

Palforzia Capsules with Logo

Aimmune Presents New Clinical Data From Patients Treated With PALFORZIA® for...

Majority of patients experienced low rates of adverse events which declined in frequency and severity with continued treatment.
Aimmune Reponse to ICER Report

Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...

Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.
AR101

New Treatment to Protect People with Peanut Allergies Ready for FDA...

"Two thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after 9 to 12 months of treatment."